After doc survery, Jefferies sees Array melanoma combo estimates as 'achievable'After conducting a poll of 31 U.S. oncologists on Array Biopharma's recently approved Braftovi/ Mektovi combo treatment for melanoma, Jefferies analyst Eun Yang said the survey leads her to believe her U.S. sales estimate of about $300M in FY2022 seems "quite achievable." Given the poll, she views downside risks for Array shares as limited and maintains a Buy rating and $18 price target on the sharesRead more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name. * Own a small position in this name $ARRY, Array BioPharma Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.